关于 Apremilast (Form B) API
治疗类别 Anti-Inflammatory
CAS 编号
608141-41-9
API 技术
合成
剂型
片剂
Dr Reddy's 开发状态
可用的
可用的法规申报文件
韩国 DMF, 中国 DMF, USDMF
Mechanism of Action
Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action in psoriatic arthritis patients and psoriasis patients is not well defined.
Indication
OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of:
- Adult patients with active psoriatic arthritis
- Patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Apremilast (Form B)（阿普米司特，B晶 型）
Anti-Inflammatory
